163 related articles for article (PubMed ID: 38474108)
1. Serum-Soluble CD163 Levels as a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma Treated with Chemoimmunotherapy.
Koudouna A; Gkioka AI; Gkiokas A; Tryfou TM; Papadatou M; Alexandropoulos A; Bartzi V; Kafasi N; Kyrtsonis MC
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474108
[TBL] [Abstract][Full Text] [Related]
2. Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma.
Andersen MN; Abildgaard N; Maniecki MB; Møller HJ; Andersen NF
Eur J Haematol; 2014 Jul; 93(1):41-7. PubMed ID: 24612259
[TBL] [Abstract][Full Text] [Related]
3. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma.
Jones K; Vari F; Keane C; Crooks P; Nourse JP; Seymour LA; Gottlieb D; Ritchie D; Gill D; Gandhi MK
Clin Cancer Res; 2013 Feb; 19(3):731-42. PubMed ID: 23224400
[TBL] [Abstract][Full Text] [Related]
4. Soluble CD163: a novel independent prognostic biomarker in patients with metastatic renal cell carcinoma.
Lauridsen KM; Hokland M; Al-Karradi S; Møller HJ; Donskov F; Andersen MN
Cancer Immunol Immunother; 2023 Feb; 72(2):461-473. PubMed ID: 35953682
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count.
Li YL; Shi ZH; Wang X; Gu KS; Zhai ZM
BMC Cancer; 2019 Nov; 19(1):1049. PubMed ID: 31694577
[TBL] [Abstract][Full Text] [Related]
6. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782
[TBL] [Abstract][Full Text] [Related]
7. Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes.
Wang J; Gao K; Lei W; Dong L; Xuan Q; Feng M; Wang J; Ye X; Jin T; Zhang Z; Zhang Q
Oncotarget; 2017 Jan; 8(3):5414-5425. PubMed ID: 28036275
[TBL] [Abstract][Full Text] [Related]
8. CD163 as a Biomarker in Colorectal Cancer: The Expression on Circulating Monocytes and Tumor-Associated Macrophages, and the Soluble Form in the Blood.
Krijgsman D; De Vries NL; Andersen MN; Skovbo A; Tollenaar RAEM; Møller HJ; Hokland M; Kuppen PJK
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824692
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of soluble CD163 as a specific marker of macrophage/monocyte activity in sarcoidosis patients.
Tanimura H; Mizuno K; Okamoto H
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Jul; 32(2):99-105. PubMed ID: 26278688
[TBL] [Abstract][Full Text] [Related]
10. Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma.
Nikkarinen A; Lokhande L; Amini RM; Jerkeman M; Porwit A; Molin D; Enblad G; Kolstad A; Räty R; Hutchings M; Weibull CE; Hollander P; Ek S; Glimelius I
Blood Adv; 2023 Sep; 7(18):5304-5313. PubMed ID: 37389827
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T
Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926
[TBL] [Abstract][Full Text] [Related]
12. Soluble CD163 is produced by monocyte-derived and alveolar macrophages, and is not associated with the severity of idiopathic pulmonary fibrosis.
Chauvin P; Morzadec C; de Latour B; Llamas-Gutierrez F; Luque-Paz D; Jouneau S; Vernhet L
Innate Immun; 2022 Apr; 28(3-4):138-151. PubMed ID: 35522300
[TBL] [Abstract][Full Text] [Related]
13. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
[TBL] [Abstract][Full Text] [Related]
14. Expression of soluble sCD163 in serum of psoriatic patients is modulated by Goeckerman therapy.
Kondelkova K; Krejsek J; Borska L; Fiala Z; Hamakova K; Andrys C
Allergol Immunopathol (Madr); 2013; 41(3):158-62. PubMed ID: 22765877
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic potential of the macrophage specific receptor CD163 in inflammatory diseases.
Buechler C; Eisinger K; Krautbauer S
Inflamm Allergy Drug Targets; 2013 Dec; 12(6):391-402. PubMed ID: 24090317
[TBL] [Abstract][Full Text] [Related]
16. Monocyte expression and soluble levels of the haemoglobin receptor (CD163/sCD163) and the mannose receptor (MR/sMR) in septic and critically ill non-septic ICU patients.
Kjærgaard AG; Rødgaard-Hansen S; Dige A; Krog J; Møller HJ; Tønnesen E
PLoS One; 2014; 9(3):e92331. PubMed ID: 24637679
[TBL] [Abstract][Full Text] [Related]
17. Increased serum levels of soluble CD163 in patients with scleroderma.
Shimizu K; Ogawa F; Yoshizaki A; Akiyama Y; Kuwatsuka Y; Okazaki S; Tomita H; Takenaka M; Sato S
Clin Rheumatol; 2012 Jul; 31(7):1059-64. PubMed ID: 22453843
[TBL] [Abstract][Full Text] [Related]
18. Soluble macrophage-derived CD163: a homogenous ectodomain protein with a dissociable haptoglobin-hemoglobin binding.
Møller HJ; Nielsen MJ; Maniecki MB; Madsen M; Moestrup SK
Immunobiology; 2010 May; 215(5):406-12. PubMed ID: 19581020
[TBL] [Abstract][Full Text] [Related]
19. Urinary Soluble CD163 Levels Predict IgA Nephropathy Remission Status.
Gong S; Jin S; Li Y; Jiang W; Zhang Z; Shen Z; Wang J; Zhou H; Liu X; Xu X; Ding X; Shi Y; Liu H
Front Immunol; 2021; 12():769802. PubMed ID: 35003086
[TBL] [Abstract][Full Text] [Related]
20. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.
Peng QL; Zhang YL; Shu XM; Yang HB; Zhang L; Chen F; Lu X; Wang GC
J Rheumatol; 2015 Jun; 42(6):979-87. PubMed ID: 25877505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]